Streetbeat News

Stock Prices

ABEV

Ambev shares are trading higher after the company reported better-than-expected Q2 sales results.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 10:40 am

MRNA

Moderna shares are trading lower after the company revised its 2024 expectations due to low EU sales, potential revenue deferrals for certain international sales into 2025, and an increasingly competitive environment for respiratory vaccines in the US.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 10:38 am

VNT

Vontier Corporation has lowered its FY24 outlook, projecting sales between $2.90 billion and $3.00 billion, down from the previous estimate of $3.04 billion to $3.10 billion. The company also adjusted its EPS forecast to $2.80-$3.00, compared to the prior view of $3.00-$3.15.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 10:38 am

AULT

Ault Alliance plans to focus on its AI data center business, rebranding itself as Hyperscale Data, Inc. and changing its ticker symbol to GPUS.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 10:37 am

ITT

ITT maintains its FY24 revenue, margin, EPS, and free cash flow guidance despite the Wolverine divestiture. The company expects revenue growth of 9% to 12%, operating margin of 16.9% to 17.5%, and adjusted EPS of $5.65 to $5.90. Free cash flow is projected to be $435 million to $475 million.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 10:35 am

ETN

Eaton Corporation has provided its Q3 adjusted EPS guidance in the range of $2.73 to $2.83, which is in line with the market estimate of $2.74.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 10:35 am

ETN

Eaton Corporation has announced its FY24 adjusted EPS guidance to be in the range of $10.65 to $10.75, surpassing the estimated $10.53.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 10:34 am

AGIO

Agios Pharmaceuticals announced that the Phase 3 ACTIVATE-KidsT study of Mitapivat in children with PK deficiency who are regularly transfused did not meet the prespecified statistical criterion for the primary endpoint.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 10:34 am

ALE

ALLETE (NYSE:ALE) reported Q2 2024 earnings per share of $0.57, missing the analyst estimate of $0.83 by 31.33%. Sales were $354.5M, missing the $547M estimate by 35.19%. Both EPS and sales showed significant declines from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 10:33 am

REGN

Regeneron Pharmaceuticals (NASDAQ:REGN) reported Q2 2024 earnings per share of $11.56, beating the analyst estimate of $10.61. The company also reported sales of $3.55 billion, surpassing the $3.38 billion estimate and marking a 12.32% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 10:33 am